Post By @CubanWindow
- Over 65,000 Cuban patients treated with Heberprot-P
A new generation of HEBERPROT-P, a leading drug in the treatment of diabetic foot in Cuba and several countries in the world, will allow in a few years to treat topically one of the most severe complications of diabetes mellitus.
It is the integration of epidermal growth factor (EGF) in a new type of nanoparticles called quatsomas, develops by the CIGB in conjunction with the Institute of Materials Sciences of Barcelona (ICMAB-CSIC).
A new hope is seen in the effort to continue reducing the rates of diabetic foot ulcer amputation and to increase the quality of life of patients suffering from this disease. However, timely prevention of these severe complications remains the most effective therapy.